Table 5.
Associations of clinical and CT features with treatment response of central ADC using univariate and multivariate logistic regression models
| Characteristics | Response group, n=42 | Nonresponse group, n=43 | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |||
| Agea | 59 (38–79) | 58 (36–81) | 1.01 (0.97–1.06) | 0.57 | 1.03 (0.97–1.08) | 0.34 |
| Sex | ||||||
| Male | 18 | 20 | Reference | – | – | |
| Female | 24 | 23 | 0.86 (0.37–2.03) | 0.74 | 1.51 (0.44–5.21) | 0.52 |
| Smoking status | ||||||
| Nonsmoker | 30 | 28 | Reference | – | – | |
| Smoker | 12 | 15 | 1.34 (0.54–3.35) | 0.53 | 1.51 (0.40–5.61) | 0.54 |
| Tumor stage | ||||||
| I–III | 24 | 18 | Reference | – | – | |
| IV | 18 | 25 | 1.85 (0.78–4.38) | 0.16 | 2.07 (0.82–5.18) | 0.12 |
| CEAa (ng/mL) | 24.67 (0.66–286.50) | 6.73 (0.28–595.20) | 1.00 (0.99–1.01) | 0.31 | – | – |
| Cyfra21-1a (ng/mL) | 7.02 (1.90–45.35) | 5.50 (1.56–84.82) | 0.99 (0.95–1.03) | 0.67 | – | – |
| NSEa (ng/mL) | 20.50 (4.42–61.54) | 17.11 (11.09–367.30) | 1.00 (0.98–1.01) | 0.50 | – | – |
| Maximal lesion sizea (cm) | 4.8 (2.6–7.8) | 5.0 (2.6–13.9) | 0.84 (0.64–1.11) | 0.22 | – | – |
| Location | – | – | ||||
| Left | 21 | 19 | Reference | – | – | |
| Right | 21 | 24 | 1.26 (0.54–2.97) | 0.59 | – | – |
| Lobulated margin | 8 | 11 | 1.46 (0.52–4.10) | 0.47 | – | – |
| Spiculated margin | 8 | 8 | 0.97 (0.33–2.88) | 0.96 | – | – |
| Air bronchogram | 5 | 4 | 0.76 (0.19–3.05) | 0.70 | – | – |
| Bronchovascular bundle convergence | 6 | 5 | 0.79 (0.22–2.82) | 0.72 | – | – |
| Pulmonary infarction | 3 | 4 | 1.33 (0.28–6.35) | 0.72 | – | – |
| Lymphangitic carcinomatosis | 3 | 5 | 1.71 (0.38–7.66) | 0.48 | – | – |
| Pulmonary emphysema | 2 | 9 | 5.29 (1.07–26.19) | 0.04 | 8.04 (1.39–46.37) | 0.02 |
| Ipsilateral hilum lymphadenopathy | 35 | 30 | 0.46 (0.16–1.31) | 0.15 | – | – |
| Contralateral hilum lymphadenopathy | 11 | 12 | 1.10 (0.42–2.84) | 0.86 | – | – |
| Mediastinal lymphadenopathy | 37 | 35 | 0.59 (0.18–1.98) | 0.39 | – | – |
| Contralateral lung metastasis | 16 | 10 | 0.49 (0.19–1.26) | 0.14 | – | – |
| Pleural nodules | 17 | 14 | 0.71 (0.29–1.72) | 0.45 | – | – |
| Interlobular fissure pleural metastasis | 7 | 9 | 1.32 (0.44–3.96) | 0.61 | – | – |
| Pleural effusion | 22 | 27 | 1.53 (0.65–3.65) | 0.33 | – | – |
| Vascular involvement | 12 | 15 | 1.34 (0.54–3.35) | 0.53 | – | – |
Note:
a
Continuous quantitative data are presented as median and range.
Abbreviations: ADC, adenocarcinoma; CEA, carcinoembryonic antigen; CT, computed tomography; Cyfra21-1, cytokeratin 19 fragment; NSE, neuron-specific enolase; OR, odds ratio.